Overexpression of interleukin-33 is associated with poor prognosis of patients with glioma

References

• Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med 2008;359(5):492–507.
   PubMed Web of Science ®Google Scholar
• Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007;114(2):97–109.
   PubMed Web of Science ®Google Scholar
• Omuro A, DeAngelis LM. Glioblastoma and other malignant gliomas: a clinical review. JAMA 2013;310(17):1842–50.
   PubMed Web of Science ®Google Scholar
• Cloughesy TF, Cavenee WK, Mischel PS. Glioblastoma: from molecular pathology to targeted treatment. Annu Rev Pathol 2014;9:1–25.
   PubMed Web of Science ®Google Scholar
• Sowers JL, Johnson KM, Conrad C, et al. The role of inflammation in brain cancer. Adv Exp Med Biol 2014;816:75–105.
   PubMed Web of Science ®Google Scholar
• Charles NA, Holland EC, Gilbertson R, et al. The brain tumor microenvironment. Glia 2012;60(3):502–14.
   PubMed Web of Science ®Google Scholar
• Mantovani A, Allavena P, Sica A, et al. Cancer-related inflammation. Nature 2008;454(7203):436–44.
   PubMed Web of Science ®Google Scholar
• Sun B, Karin M. The therapeutic value of targeting inflammation in gastrointestinal cancers. Trends Pharmacol Sci 2014;35(7):349–57.
   PubMed Web of Science ®Google Scholar
• Liew FY, Pitman NI, McInnes IB. Disease-associated functions of IL-33: the new kid in the IL-1 family. Nat Rev Immunol 2010;10(2):103–10.
   PubMed Web of Science ®Google Scholar
• Cayrol C, Girard JP. IL-33: an alarmin cytokine with crucial roles in innate immunity, inflammation and allergy. Curr Opin Immunol 2014;31:31–7.
   PubMed Web of Science ®Google Scholar
• Mirchandani AS, Salmond RJ, Liew FY. Interleukin-33 and the function of innate lymphoid cells. Trends Immunol 2012;33(8):389–96.
   PubMed Web of Science ®Google Scholar
• Hu LA, Fu Y, Zhang DN, et al. Serum IL-33 as a diagnostic and prognostic marker in non- small cell lung cancer. Asian Pac J Cancer Prev 2013;14(4):2563–6.
   PubMedGoogle Scholar
• Bergis D, Kassis V, Ranglack A, et al. High serum levels of the interleukin-33 receptor soluble ST2 as a negative prognostic factor in hepatocellular carcinoma. Transl Oncol 2013;6(3):311–8.
   PubMed Web of Science ®Google Scholar
• Schmieder A, Multhoff G, Radons J. Interleukin-33 acts as a pro-inflammatory cytokine and modulates its receptor gene expression in highly metastatic human pancreatic carcinoma cells. Cytokine 2012;60(2):514–21.
   PubMed Web of Science ®Google Scholar
• Liu R, Page M, Solheim K, et al. Quality of life in adults with brain tumors: current knowledge and future directions. Neuro Oncol 2009;11(3):330–9.
   PubMed Web of Science ®Google Scholar
• Bradford MM. Rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248–54.
   PubMed Web of Science ®Google Scholar
• Xu T, Qin R, Zhou J, et al. High bone sialoprotein (BSP) expression correlates with increased tumor grade and predicts a poorer prognosis of high-grade glioma patients. PLoS One 2012;7:e48415.
   PubMed Web of Science ®Google Scholar
• Zhao Q, Chen GJ. Role of IL-33 and its receptor in T cell-mediated autoimmune diseases. BioMed Res Int 2014;2014:587376.
   PubMed Web of Science ®Google Scholar
• Wang S, Ding L, Liu SS, et al. IL-33: a potential therapeutic target in autoimmune diseases. J Investig Med 2012;60(8):1151–6.
   PubMed Web of Science ®Google Scholar
• Kamekura R, Kojima T, Takano K, et al. The role of IL-33 and its receptor ST2 in human nasal epithelium with allergic rhinitis. Clin Exp Allergy 2012;42(2):218–8.
   PubMed Web of Science ®Google Scholar
• Hung LY, Lewkowich IP, Dawson LA, et al. IL-33 drives biphasic IL-13 production for noncanonical Type 2 immunity against hookworms. Proc Natl Acad Sci U.S.A 2013;110(1):282–7.
   PubMed Web of Science ®Google Scholar
• Rostan O, Gangneux JP, Piquet-Pellorce C, et al. The IL-33/ST2 axis is associated with human visceral leishmaniasis and suppresses Th1 responses in the livers of BALB/c mice infected with Leishmania donovani. MBio 2013;4(5):e00383–13.
   Web of Science ®Google Scholar
• Liang Y, Jie Z, Hou L, et al. IL-33 induces nuocytes and modulates liver injury in viral hepatitis. J Immunol 2013;190(11):5666–75.
   PubMed Web of Science ®Google Scholar
• Rostan O, Arshad MI, Piquet-Pellorce C, et al. Crucial and diverse role of the interleukin-33/ST2 axis in infectious diseases. Infect Immun 2015;83(5):1738–48.
   PubMed Web of Science ®Google Scholar
• Sun P, Ben Q, Tu S, et al. Serum interleukin-33 levels in patients with gastric cancer. Dig Dis Sci 2011;56(12):3596–601.
   PubMed Web of Science ®Google Scholar
• Zhang P, Liu XK, Chu Z, et al. Detection of interleukin-33 in serum and carcinoma tissue from patients with hepatocellular carcinoma and its clinical implications. J Int Med Res 2012;40(5):1654–61.
   PubMed Web of Science ®Google Scholar
• Santulli P, Even M, Chouzenoux S, et al. Profibrotic interleukin-33 is correlated with uterine leiomyoma tumour burden. Hum Reprod 2013;28(8):2126–33.
   PubMed Web of Science ®Google Scholar
• Liu X, Zhu L, Lu X, et al. IL-33/ST2 pathway contributes to metastasis of human colorectal cancer. Biochem Biophys Res Commun 2014;453(3):486–92.
   PubMed Web of Science ®Google Scholar
• Liu J, Shen JX, Hu JL, et al. Significance of interleukin-33 and its related cytokines in patients with breast cancers. Front Immunol 2014;5:141.
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research Network, Weinstein JN, Collisson EA, et al. The Cancer Genome Atlas Pan-Cancer analysis project. Nat Genet 2013;45(10):1113–20.
   PubMed Web of Science ®Google Scholar
• Chen XJ, Huang YD, Li N, et al. Correlations between serum IL33 and tumor development: a meta-analysis. Asian Pac J Cancer Prev 2014;15(8):3503–5.
   PubMedGoogle Scholar
• Chen SF, Nieh S, Jao SW, et al. The paracrine effect of cancer-associated fibroblast-induced interleukin-33 regulates the invasiveness of head and neck squamous cell carcinoma. J Pathol 2013;231(2):180–9.
   PubMed Web of Science ®Google Scholar
• Yu XX, Hu Z, Shen X, et al. IL-33 promotes gastric cancer cell invasion and migration via ST2-ERK1/2 pathway. Dig Dis Sci 2015;60(5):1265–72.
   PubMed Web of Science ®Google Scholar
• Kim JY, Lim SC, Kim G, et al. Interleukin-33/ST2 axis promotes epithelial cell transformation and breast tumorigenesis via upregulation of COT activity. Oncogene 2015;34(38):4928–38.
   PubMed Web of Science ®Google Scholar
• Fang KM, Yang CS, Lin TC, et al. Induced interleukin-33 expression enhances the tumorigenic activity of rat glioma cells. Neuro Oncol 2014;16(4):552–66.
   PubMed Web of Science ®Google Scholar
• Shaw EG, Scheithauer BW, O'Fallon JR. Supratentorial gliomas: a comparative study by grade and histologic type. J Neurooncol 1997;31(3):273–8.
   PubMed Web of Science ®Google Scholar